Suspended
UWFA-RVO-MEUltra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
What is being collected
Data Collection
Collected from today forward - ProspectiveWho is being recruted
Cardiovascular Diseases+8
+ Eye Diseases
+ Macular Degeneration
Over 18 Years
+14 Eligibility Criteria
How is the trial designed
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Observational
Study Start: October 2023
Summary
Principal SponsorRenmin Hospital of Wuhan University
Study ContactCZ Chen, PHD
Last updated: January 28, 2026Sourced from a government-validated database.Claim as a partner
Study start date: October 9, 2023
Actual date on which the first participant was enrolled.Ultra-wide field fluorescence angiography can clearly observe the peripheral retina. This study mainly observes the ischemic index and vascular leakage index changes on UWFA after anti-VEGF treatment and evaluates these changes associated with treatment efficacy in patients with macular edema secondary to retinal vein occlusion.
Official TitleUltra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
Principal SponsorRenmin Hospital of Wuhan University
Study ContactCZ Chen, PHD
Last updated: January 28, 2026Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
60 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Cardiovascular DiseasesEye DiseasesMacular DegenerationMacular EdemaRetinal DegenerationRetinal DiseasesRetinal Vein OcclusionThrombosisVascular DiseasesEmbolism and ThrombosisVenous Thrombosis
Criteria
5 inclusion criteria required to participate
Male or female aged 18 years or older
Macular edema secondary to CRVO,BRVO or HRVO
Duration of RVO not more than 4 months
Naïve patients. Patient with previous RVO (more than 12 months before the inclusion date) completely resolved (normalization of visual acuity and fundus examination) and who have experienced a recurrence of RVO are also considered naive
Show More Criteria
9 exclusion criteria prevent from participating
Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period
Active or suspected ocular or periocular infection
Active severe intraocular inflammation
RVO complicated with neovascularization
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Recruiting
Renmin Hospital of Wuhan University
Wuhan, ChinaOpen Renmin Hospital of Wuhan University in Google MapsSuspendedOne Study Center